Athira Pharma has completed enrollment of the first group of healthy volunteers who’ll receive a single dose of ATH-1105, its experimental oral therapy for amyotrophic lateral sclerosis (ALS), in a Phase 1 clinical trial. The Phase 1 trial (NCT 06432647),…

After up to 3.5 years on the experimental oral treatment CNM-Au8, the chances of survival for people with amyotrophic lateral sclerosis (ALS) in the open-label extension of the HEALEY ALS platform trial was nearly 60% higher than for a group of patients given a placebo in previous studies.

Adding Radicava (edaravone) to riluzole prolongs survival of amyotrophic lateral sclerosis (ALS) patients by more than three months relative to riluzole alone, according to analyses of real-world data from the ALS/MND Natural History Study Consortium database. These and other Radicava-related findings were presented by the therapy’s developer…

COYA 302, Coya Therapeutics’ experimental immune-modulating combination therapy, safely slows disease progression and reduces levels of disease biomarkers in people with amyotrophic lateral sclerosis (ALS). That’s according to the now-published results from a small proof-of-concept Phase 1 clinical trial (NCT06307301) that tested the therapy in four ALS…

People with amyotrophic lateral sclerosis (ALS) who are treated by a neurologist are more likely to receive evidence-based care endorsed by the American Academy of Neurology than those who see non-neurologist providers, according to an analysis of Medicare data. Still, fewer than half of the ALS patients studied…

The nonprofit organization ALS Northwest has partnered with the Oregon State Treasury to establish a college scholarship program through the state-administered Oregon College Savings Plan for students who have lost parents or guardians to amyotrophic lateral sclerosis (ALS). ALS Northwest will administer the Elinore Nudelman ALS College…

Eli Lilly has acquired the global exclusive rights to develop and market QRL-204, QurAlis’ investigational therapy for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) that’s designed to restore UNC13A function in nerve cells. UNC13A is an essential regulator of neurotransmitter release at synapses, a key process…

The U.S. Department of Defense (DoD) has awarded more than $2 million to help Pathmaker Neurosystems conduct a second clinical trial of its MyoRegulator — an experimental, noninvasive nerve modulating device — in people with amyotrophic lateral sclerosis (ALS). “We are very pleased to have…

An advisory committee of the European Medicines Agency (EMA) is leaning against recommending the conditional approval of AB Science’s masitinib as an oral add-on treatment for amyotrophic lateral sclerosis (ALS), the company has announced in a press release. The Committee for Medicinal Products for Human Use (CHMP)…

Increasing levels of the MIF protein may be a promising therapeutic strategy for slowing disease progression in amyotrophic lateral sclerosis (ALS), a study found. This approach in a mouse model of ALS with mutations in the SOD1 gene preserved motor function and prolonged survival, while lowering neuroinflammation and restoring…